Somnomed Limited · ASX:SOM
Somnomed — Investor Presentation (2020)
30 slides from Somnomed's investor presentation, 2020
Slide 1: Investor Presentation FY2020
Investor Presentation FY2020
Slide 2: Disclaimer & Regulatory Disclosure
DISCLAIMER & REGULATORY DISCLOSURE This document has been prepared as a summary only, and does not contain all information about the Company’s assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s securities. This docu
Slide 3: Treatment focused, Technology driven
Treatment focused Technology driven
Slide 4: Agenda
1.FY20 results summary 2.COVID-19 3.Vision & market opportunity 4.Financial information 5.Future horizons update 6.Outlook FY21
Slide 5: 1. FY20 results summary
1. FY20 results summary @ SomnoMVed
Slide 6: FY20 summary
FY20 summary SomnoMed’s core revenues $57m and -3% to prior year Successful acceptance and adoption of the digital SomnoDent® Avant EBITDA* $4.7m and -5% to prior year underlying EBITDA* App-Nea software providing a connectivity network North America revenue growth 9 months to March 2020 between den
Slide 7: 2. COVID-19
2. COVID-19 @ SomnoMVed
Slide 8: COVID-19
COVID-19 Responded quickly to ensure financial safety: Staff safety was paramount with limited office attendance, strict social distancing, testing if symptoms were displayed • raised $15.5m to protect the business and travel support • implemented immediate cost saving measures Constant, open, trans
Slide 9: 3. Vision & market opportunity
3. Vision & market opportunity
Slide 10: Vision/Mission
Vision/Mission Vision: SomnoMed will be a leader in the treatment of patients suffering from obstructive sleep apnea and relevant adjacent conditions Mission: Advancing the acceptance and adoption of the treatment therapies by medical specialists, dentists, patients and insurers https://somnomed.com
Slide 11: Obstructive Sleep Apnea
SOMNOMED Obstructive Sleep Apnea Obstructive sleep apnea is a disorder that occurs when a person’s breathing is interrupted during sleep because the airway becomes blocked 11 11
Slide 12: Market Opportunity
MARKET OPPORTUNITY OSA Market COAT™ Market 1.36 billion patients suffer with OSA globally There is a high ceiling for COAT™ growth Moderate & severe OSA 400M patients Mild OSA 936M patients Benjafield et.al : Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature- S
Slide 13: CPAP therapy compliance – first dilemma
CPAP therapy compliance – first dilemma 50% of patients do not use CPAP after 6 months* Clinical Insight “The findings are sobering. Our data suggest that despite numerous changes to machine and mask dynamics as well as behavioral interventions, CPAP adherence remains a severe problem for management
Slide 14: Comparison of CPAP and COAT
CPAP therapy compliance – second dilemma Many patients don’t get effective treatment all night, every night Comparison of CPAP and COAT™ Compares CPAP and COAT™ over a complete night’s sleep Interactive sales tool that allows Sleep Physicians to determine which therapy is more effective for thei
Slide 15: SomnoMed core strengths
SomnoMed core strengths Leader in the oral appliance treatment of Obstructive Sleep Apnea Design and Manufacturing Sales and Service and innovation distribution support Traditional Titration methodology Strong market brand Technical support Digital done right Product range Direct global footprint Be
Slide 16: SomnoMed's competitive advantage
SomnoMed’s competitive advantage Strong clinical research supporting COAT™ therapy Design and innovation driving patient comfort Unrivalled, comprehensive product range Proprietary materials Unique and patented titration methodology (SomnoDent® Avant) Growing and extensive sales and distribution foo
Slide 17: The patient preferred alternative
The patient preferred alternative SomnoMed is the world leader in oral appliances with over 565,000 patients treated worldwide https://somnomed.com 17
Slide 18: 4. Financial information
4. Financial information @ SomnoMVed
Slide 19: Financials
Financials Total SomnoMed core revenue growth https://somnomed.com 19
Slide 20: Financials: Core revenue growth by region
Financials Core revenue growth by region https://somnomed.com 20
Slide 21: Revenue and Gross Margin Breakdown
Financials Revenue and Gross Margin Breakdown % Gross Margin 69% 88% 4% 58% of Revenues https://somnomed.com 21
Slide 22: SomnoMed Core EBITDA protected
Financials SomnoMed Core EBITDA* protected A$ ‘000 * EBITDA as adjusted does not include share option expense, gain on contingent consideration payable, impairment of goodwill, effects of AASB16 and discontinued operations https://somnomed.com 22
Slide 23: Financial Summary - AUD $000's
Financial Summary - AUD $000's SomnoMed FY20 FY19 % Regional sales and marketing expenses Revenue 57,296 58,892 -3% Managed by region and individual market to same levels as PY Gross margin 33,100 34,572 -4% Regional sales and marketing expenses (15,437) (14,967) 3% Regional administrative expenses
Slide 24: Summary Balance Sheet and Cash Flow
Summary Balance Sheet and Cash Flow Statement of cash flows - AUD $m Statement of financial position - AUD $m Statutory Statutory Statutory Statutory FY20 FY19 30-Jun-20 30-Jun-19 $ million $ million EBITDA* CORE 4.7 3.4 Cash and cash equivalents 30.2 7.7 EBITDA* RSS** - (9.5) Inventories 2.2 1.9 EB
Slide 25: 5. Future horizons update
5. Future horizons update @ SomnoMVed
Slide 26: Our future horizons
Our future horizons Advancing treatment Positioning “the Technology & building the core patient’s alternative” driven Sales and marketing focus and Effective medical outcome of Digital manufacturing investment globally COAT™ versus CPAP Technology bridge through Medical initiative focus Partnerships
Slide 27: 6. Outlook FY21
6. Outlook FY21 @ SomnoMVed
Slide 28: Outlook FY21
Outlook FY21 Year of two distinct halves First half : restore and recover, respond to changing market conditions, stabilize Second half : rebuild and grow, execute on strategic initiatives, optimise Regional Europe – market fundamentals remain sound, reimbursement trends positive, focus on medical a
Slide 29: Treatment focused, Technology driven
Treatment focused Technology driven
Slide 30: Contact
Contact Chief Executive Officer: Mr Neil Verdal-Austin Chief Financial Officer: Mr Hervé Fiévet Address: 20 Clarke Street, Crows Nest, Sydney 2065 Telephone: 02 9467 0400 Website: www.somnomed.com